MarketsAurobindo Pharma Limited AUROPHARMA
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
Daily technical summary
Calculated in the browser from validated historical candles. This is descriptive research, not a buy or sell recommendation.
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 58,502.15 | 49,784.97 | 45,071.51 |
| Cash Equivalents | 9,870.29 | 2,919.57 | 2,110.91 |
| Other Liabilities Total | 1,178.64 | 351.57 | 277.59 |
| Long Term Debt | 802.75 | 1,561.65 | 2,134.9 |
| Common Stock Total | 58.08 | 58.08 | 58.59 |
| Other Current Assets Total | 2,803.41 | 43.13 | 445.24 |
| Total Assets | 58,502.15 | 49,784.97 | 45,071.51 |
| Current Portof LT Debt/Capital Leases | 6,977.15 | 1,152.29 | 182.08 |
| Total Equity | 37,890.97 | 32,653.32 | 29,842.8 |
| Long Term Investments | 853.78 | 251.7 | 321.65 |
| Retained Earnings(Accumulated Deficit) | 37,832.89 | 30,681.61 | 27,848.33 |
| Total Common Shares Outstanding | 58.08 | 58.08 | 58.59 |
| Tangible Book Valueper Share Common Eq | 561.46 | 489.23 | 439.74 |
| Goodwill Net | 800.15 | 618.02 | 595.15 |
| Total Liabilities | 20,611.18 | 17,131.65 | 15,228.71 |
| Total Debt | 8,072.84 | 8,262.87 | 6,647.63 |
| Short Term Investments | 848.19 | 2,632.33 | 2,932.88 |
| Cashand Short Term Investments | 10,718.48 | 8,201.28 | 6,326.36 |
| Total Receivables Net | 7,133.92 | 8,374.33 | 7,625.8 |
| Deferred Income Tax | 306 | 303.27 | 356.56 |
| Accounts Receivable-Trade Net | 7,094.37 | 5,873.95 | 5,036.43 |
| Property/Plant/Equipment Total-Net | 17,338.76 | 15,455.43 | 14,284.9 |
| Minority Interest | -8.16 | -6.39 | 8 |
| Total Current Liabilities | 18,039.01 | 14,682.34 | 12,199.13 |
| Total Inventory | 12,052.94 | 10,543.72 | 9,808.23 |
| Accounts Payable | 5,567.27 | 4,188.85 | 4,454.16 |
| Other Currentliabilities Total | 5,494.59 | 3,785.22 | 3,138.51 |
| Total Long Term Debt | 1,095.69 | 1,800.86 | 2,387.43 |
| Intangibles Net | 4,481.23 | 3,620.7 | 3,481.46 |
| Other Long Term Assets Total | 1,859.48 | 1,468.33 | 1,366.35 |
| Note Receivable-Long Term | 460 | 1,208.33 | 816.37 |
| Total Current Assets | 32,708.75 | 27,162.46 | 24,205.63 |
| Capital Lease Obligations | 292.94 | 239.21 | 252.53 |
| Accumulated Depreciation Total | Not available | -6,538.47 | -6,372.69 |
| Accrued Expenses | Not available | 246.26 | 346.26 |
| Other Equity Total | Not available | 1,838.52 | 1,517.99 |
| Additional Paid-In Capital | Not available | 75.11 | 417.89 |
| Cash | Not available | 2,649.38 | 1,282.57 |
| Property/Plant/Equipment Total-Gross | Not available | 18,727.9 | 17,918.2 |
| Notes Payable/Short Term Debt | Not available | 5,309.72 | 4,078.12 |
Valuation and ratios
Valuation
PEG Ratio1.17
Price to Sale Ratio0.26
Growth
Debt 5Yr CAGR %8.41
Margins
Operating Margin 12m14.89
Operating Margin 5y Avg13.78
Net Profit Margin 12m10.41
Net Profit Margin 5y10.32
Yield
Dividend Yield %0.25
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk29.03
Recommendations
RatingBuy
Target High1,636
Target Low1,017
Target Mean2.22
Target Median52.78
Analyst count, source and as-of date are not provided; target values should be treated as unverified.Peer comparison
Only peers present in the company profile payload are displayed.
| Symbol | Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|---|
| — | Neuland Laboratories | INR 18,450 | 23,737.18 | 64.28 | — |
| — | Pfizer | INR 4,597.85 | 20,988.27 | 27.53 | — |
| — | Unichem Laboratories | INR 534.55 | 3,763.54 | 54.27 | — |
| — | Jagsonpal Pharmaceuticals | INR 222 | 1,456.38 | 34.27 | — |
| — | Themis Medicare | INR 110.2 | 1,015.38 | 632.19 | — |
Ownership
- Promoter
- 51.88%
- FII
- 16.38%
- MF
- 16.71%
- Other
- 15.03%
Events
- board MeetingsAudited Results
- annual General MeetingBuy Back of Shares
- board MeetingsBuy Back of Shares
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.4.0000 per share(400%)Interim Dividend
- board MeetingsQuarterly Results & Interim Dividend
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- annual General MeetingBuy Back of Shares
- board MeetingsTo consider buyback for equity shares
- board MeetingsAudited Results
- annual General MeetingPOM
- dividendRs.1.5000 per share(150%)Second Interim Dividend
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Voltas, Auro Pharma, Federal Bank: Stocks to trade—check price targets, stop loss & more MSN
Aurobindo Pharma launches TheraNym, India’s largest biologics CMO Indian Pharma Post
USFDA Clears Aurobindo Pharma's Generic Xeljanz Tablets for Arthritis, Ulcerative Colitis Medical Dialogues
Aurobindo Pharma - Retail investors' picks: 11 high-margin stocks surge up to 40% in CY26 The Economic Times
Aurobindo Pharma officials to attend UBS virtual investor meet scanx.trade
Aurobindo Pharma gains on getting USFDA`s final nod for Tofacitinib Tablets Investment Guru India
Aurobindo Pharma Launches TheraNym, Large-Scale Biologics Contract Manufacturing Facility in Telangana Machine Maker
Aurobindo Pharma gains after receiving USFDA approval for Tofacitinib tablets Business Standard
Business information
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology, non-oncology prescription formulation, and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is marketing its products globally in approximately 150 countries. Its subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltd, and others.
- Industry
- Major Drugs
- Sector
- Major Drugs
- Website
- Not available
- Address
- Not available
- NSE Code
- AUROPHARMA
- BSE Code
- 524804
AI analysis
This repository contains no authenticated model-inference API, model version, confidence distribution or forecast timestamp. The Android listing is available; verify report availability, entitlement and pricing inside the app.
Open Google PlayStock FAQ
What is the symbol and ISIN of Aurobindo Pharma?
Aurobindo Pharma has the symbol AUROPHARMA and ISIN - INE406A01037.
What is the current price of Aurobindo Pharma?
Aurobindo Pharma is currently trading at INR 1,535.00.
What are the year high and year low of Aurobindo Pharma?
Aurobindo Pharma has a year high of INR 1,636.00 and a year low of INR 1,017.00.
What is the market capitalization of Aurobindo Pharma?
Aurobindo Pharma has a market capitalization of INR 87,540.38 crore.
What is the P/E ratio of Aurobindo Pharma?
Aurobindo Pharma has a P/E ratio of 21.62.
What is the dividend yield of Aurobindo Pharma?
Aurobindo Pharma has a dividend yield of 0.25%.
How is the financial performance of Aurobindo Pharma based on revenue, net income, and EPS?
Aurobindo Pharma has revenue of INR 3,36,530.80 crore, net income of INR 35,047.50 crore, and EPS of INR 61.10.
What is the book value of Aurobindo Pharma?
Aurobindo Pharma has a book value of INR 561.46.
What is the debt-to-equity ratio of Aurobindo Pharma?
Aurobindo Pharma has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Aurobindo Pharma?
Aurobindo Pharma has a price-to-book ratio of 2.73 and a price-to-sales ratio of 0.26.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.
